Switch theme
Sign up to access all valuation multiples
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for detecting diseases of significance to public health. Its ophthalmic diagnostic solutions includes intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company's geographical segments include Finland, USA, and Others.
2001
241
LTM Revenue $121M
LTM EBITDA $36.2M
$783M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Revenio Group has a last 12-month revenue (LTM) of $121M and a last 12-month EBITDA of $36.2M.
In the most recent fiscal year, Revenio Group achieved revenue of $116M and an EBITDA of $34.3M.
Revenio Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Revenio Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $121M | XXX | $116M | XXX | XXX | XXX |
| Gross Profit | $68.9M | XXX | $81.9M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $36.2M | XXX | $34.3M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $31.2M | XXX | $28.1M | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $22.5M | XXX | $20.8M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Revenio Group's stock price is EUR 27 (or $30).
Revenio Group has current market cap of EUR 717M (or $805M), and EV of EUR 697M (or $783M).
See Revenio Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $783M | $805M | XXX | XXX | XXX | XXX | $0.88 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Revenio Group has market cap of $805M and EV of $783M.
Revenio Group's trades at 6.7x EV/Revenue multiple, and 22.9x EV/EBITDA.
Equity research analysts estimate Revenio Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Revenio Group has a P/E ratio of 35.8x.
See valuation multiples for Revenio Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $805M | XXX | $805M | XXX | XXX | XXX |
| EV (current) | $783M | XXX | $783M | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | 21.6x | XXX | 22.9x | XXX | XXX | XXX |
| EV/EBIT | 25.1x | XXX | 27.8x | XXX | XXX | XXX |
| EV/Gross Profit | 11.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 35.8x | XXX | 38.8x | XXX | XXX | XXX |
| EV/FCF | 38.0x | XXX | 35.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRevenio Group's last 12 month revenue growth is 11%
Revenio Group's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.2M for the same period.
Revenio Group's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Revenio Group's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Revenio Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 42% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Revenio Group acquired XXX companies to date.
Last acquisition by Revenio Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Revenio Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Revenio Group founded? | Revenio Group was founded in 2001. |
| Where is Revenio Group headquartered? | Revenio Group is headquartered in Finland. |
| How many employees does Revenio Group have? | As of today, Revenio Group has 241 employees. |
| Who is the CEO of Revenio Group? | Revenio Group's CEO is Mr. Jouni Toijala. |
| Is Revenio Group publicy listed? | Yes, Revenio Group is a public company listed on HEL. |
| What is the stock symbol of Revenio Group? | Revenio Group trades under REG1V ticker. |
| When did Revenio Group go public? | Revenio Group went public in 2001. |
| Who are competitors of Revenio Group? | Similar companies to Revenio Group include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Revenio Group? | Revenio Group's current market cap is $805M |
| What is the current revenue of Revenio Group? | Revenio Group's last 12 months revenue is $121M. |
| What is the current revenue growth of Revenio Group? | Revenio Group revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Revenio Group? | Current revenue multiple of Revenio Group is 6.5x. |
| Is Revenio Group profitable? | Yes, Revenio Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Revenio Group? | Revenio Group's last 12 months EBITDA is $36.2M. |
| What is Revenio Group's EBITDA margin? | Revenio Group's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Revenio Group? | Current EBITDA multiple of Revenio Group is 21.6x. |
| What is the current FCF of Revenio Group? | Revenio Group's last 12 months FCF is $20.6M. |
| What is Revenio Group's FCF margin? | Revenio Group's last 12 months FCF margin is 17%. |
| What is the current EV/FCF multiple of Revenio Group? | Current FCF multiple of Revenio Group is 38.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
